At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 109 enrolled
Drug / intervention
Omaveloxolone Ophthalmic Suspension 1.0% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Dose-Ranging, Double-Masked, Placebo-Controlled Phase 2 Study Evaluating the Safety and Efficacy of RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery
In Brief
A Phase 2 clinical trial evaluating Omaveloxolone Ophthalmic Suspension 1.0%, Omaveloxolone Opthalmic Suspension 0.5%, and 1 other intervention for Inflammation and Pain Following Ocular Surgery. Completed, enrolled 109 participants across 6 sites.
Detailed Summary
This study assesses the efficacy and safety of two concentrations of RTA 408 Ophthalmic Suspension in the treatment of patients who have inflammation and pain following ocular surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsAbbVie
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 2014
Enrollment StartFeb 2014
Primary CompletionSep 2014
TodayJul 2026
First PostedFeb 19, 2014
Enrollment StartFeb 28, 2014
Primary CompletionSep 30, 2014
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.4 years ago
Interventions
Omaveloxolone Ophthalmic Suspension 1.0%drug
Omaveloxolone Opthalmic Suspension 0.5%drug
Placebodrug